Roche Holding AG (RHHBY)
| Market Cap | 326.63B +28.9% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 20.11 |
| Forward PE | 15.55 |
| Dividend | 0.97 (1.91%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 306,301 |
| Average Volume | 2,596,100 |
| Open | 50.92 |
| Previous Close | 51.09 |
| Day's Range | 50.82 - 51.36 |
| 52-Week Range | 37.51 - 60.85 |
| Beta | 0.33 |
| RSI | 50.36 |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more th...
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Basel, 19 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical ...
Roche, Medicines Patent Pool sign deal to expand access to influenza drug
Roche and the Medicines Patent Pool have signed a licensing agreement to expand access to the Swiss drugmaker's flu drug, Xofluza, in low- and middle-income countries, the organizations said on Monda...
FDA approves Genentech’s Tecentriq for adjuvant muscle-invasive bladder cancer
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Tecentriq and Tecentriq Hybreza as an adjuvant treatment for adult patients with…
FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentr...
Roche's Diagnostics Day 2026 Transcript
Roche's Diagnostics Day 2026 Transcript
Roche gets European approval for Alzheimer’s diagnosis blood test
Swiss pharmaceutical company Roche has received European approval for a blood test that can detect and rule out Alzheimer’s disease, offering a simpler and less invasive alternative to current diagnos...
Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030
The drugmaker's on-market pharma portfolio, together with drugs for lupus, breast cancer and multiple sclerosis, should offset generic competition until 2030, Chief Executive Thomas Schinecker said.
Roche receives CE Mark for Elecsys pTau217
Roche (RHHBY) announced that it has received CE Mark for Elecsys pTau217, a blood test developed in collaboration with Eli Lilly and Company (LLY) and designed to measure the phosphorylated…
Roche Holding AG Transcript: Roche Diagnostics Day 2026
The event outlined a strategy centered on innovation, digital integration, and targeted growth in high-burden disease areas. Key launches like AXELIOS sequencing and CGM are set to drive mid to high single-digit sales growth, with profit outpacing sales, supported by strategic acquisitions and a robust pipeline.
Roche Holding AG Slides: FY 2026
Roche Holding AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 12, 2026.
Roche gets second European approval for Alzheimer's test
Swiss drugmaker Roche has received the CE mark - a European regulatory clearance allowing sale in the region - for its second Elecsys blood test for Alzheimer's disease, it said on Tuesday.
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Basel, 12 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and design...
Roche (RHHBF) to Acquire PathAI for $1.1B to Enhance Digital Pathology Services
Roche (RHHBF) to Acquire PathAI for $1.1B to Enhance Digital Pathology Services
Roche Acquires PathAI for $750 Million, Stock Impact Expected
Roche Acquires PathAI for $750 Million, Stock Impact Expected
Roche announces agreement to acquire PathAI
Roche (RHHBY) announced that it has entered into a definitive merger agreement to acquire PathAI, a U.S.-based company in digital pathology and AI-powered technology for pathology laboratories and the...
Roche Enters $750 Mln Merger Deal To Acquire PathAI To Expand AI-Driven Diagnostics
(RTTNews) - Roche (RHHBY), a healthcare company, announced on Thursday that it has entered into a definitive merger agreement to acquire PathAI, a digital, AI-powered technology firm serving pathology...
Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools
The deal seeks to bolster the artificial-intelligence offerings of Roche's diagnostics division, helping to accelerate clinical-therapy development.
Switzerland's Roche agrees to acquire US-based PathAI
Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further miles...
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
Basel, 7 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered...
The Zacks Analyst Blog Highlights Microsoft, Bank of America, Roche and GSI Technology
Microsoft faces pressure from capacity constraints and competition, even as AI momentum and Azure growth drive demand beyond available supply.
Top Analyst Reports for Microsoft, Bank of America & Roche
Microsoft faces Azure capacity limits and rising competition, but AI momentum and Copilot adoption fuel cloud growth and enterprise demand.
Roche To Showcase Broad Ophthalmology Data Portfolio At ARVO 2026, Today
(RTTNews) - Roche (RHHBY) will present one of the largest ophthalmology data packages at this year's ARVO Annual Meeting, highlighting new real-world findings and clinical updates across its marketed ...
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will showcase key real-world, product and pipeline data from ...
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
Basel, 30 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association for Resear...